Clinical Trial Update: A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer [Phase 2]

View source ↗

Summary

A Phase II trial of the DNA methyltransferase inhibitor guadecitabine (SGI-110) in children and adults with wild-type GIST, paraganglioma, pheochromocytoma, and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumor
• Hereditary Leiomyomatosis and Renal Cell Carcinoma
• Paraganglioma
• Pheochromocytoma
• Renal Cell Carcinoma

Drugs mentioned

• Guadecitabine (guadecitabine)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Paraganglioma, Gastrointestinal Stromal Tumors | Phase 2 | Status: TERMINATED | Results posted: 2021-05-10